A rare genetic condition that typically kills infants and young adults through aggressive kidney stone formation may finally have an effective treatment option. Primary hyperoxaluria type 2 affects roughly one in 100,000 people worldwide, causing the body to overproduce oxalate, leading to massive calcium oxalate crystal deposits that destroy kidney function within months of onset. Current interventions offer minimal benefit, making organ transplantation the only viable option for most patients.
Researchers testing N-propargylglycine (N-PPG) in genetically modified mice found the oral compound completely prevented stone formation while extending survival from a median 15 weeks to beyond 24 weeks. The treatment works by inhibiting hydroxyproline dehydrogenase, a liver enzyme that produces the excess glyoxylate ultimately converted to oxalate. Within three weeks, treated mice showed dramatically reduced oxalate levels, preserved kidney function markers, and prevented the tubular damage that characterizes this devastating condition.
This represents a potential paradigm shift for primary hyperoxaluria management. While enzyme replacement therapies and RNA interference treatments have shown promise in related conditions, N-PPG's simple oral administration and complete prevention of disease progression in this lethal model suggests remarkable therapeutic potential. The compound's ability to target the upstream metabolic pathway rather than merely managing downstream effects could revolutionize care for these patients. However, mouse models don't always translate to human efficacy, and the long-term safety profile in humans remains unknown. Given the current lack of effective treatments and the condition's rapid lethality, this early preclinical success warrants accelerated clinical investigation.